Literature DB >> 35259713

A validated LC-MS/MS method for the quantitation of cefazolin in human adipose tissue: Application of EMR-Lipid sorbent as an efficient sample clean-up before mass spectrometric analyses.

Anna Siemiątkowska1, Andrew Wassef2, Ragui Sadek3, Celine Park4, Christine Yohn5, Luigi Brunetti6, Leonid Kagan7.   

Abstract

A novel, simple, rapid, and sensitive high-performance liquid chromatography-tandem mass spectrometry method was developed to determine cefazolin concentrations in human adipose tissue. Sample preparation was performed by protein precipitation followed by using Captiva EMR-Lipid plates. The mobile phase consisted of 5 mM ammonium formate and 0.1% formic acid in water and 0.1% formic acid in ACN, and was pumped through a Synergi Fusion-RP column with a gradient elution program at a flow rate of 0.3 mL/min. The mass spectrometer was operated in a positive ion mode. Cloxacillin was used as an internal standard due to the observed cross-signal contribution between cefazolin and 13C2,15N-cefazolin. The method was validated according to the FDA and EMA guidelines and passed all the acceptance criteria. The calibration range was 0.05-50 µg/mL in adipose tissue homogenate (0.15-150 µg/g in adipose tissue), precision CV < 4.5%, accuracy within 93.1-100.4%. The carry-over was negligible, recovery of the method was high, and no significant matrix effect was present. Rat subcutaneous adipose tissue was demonstrated to be a suitable surrogate matrix for human adipose tissue. The validated method was successfully applied in a pilot pharmacokinetic study and will further be used in a large cohort of non-obese and obese patients dosed prophylactically with cefazolin before surgeries.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analyte–to–IS signal contribution; Antibiotics; Method validation; Obesity; Phospholipids removal; Surrogate matrix

Mesh:

Substances:

Year:  2022        PMID: 35259713      PMCID: PMC9034060          DOI: 10.1016/j.jpba.2022.114696

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.571


  30 in total

1.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.

Authors:  B K Matuszewski; M L Constanzer; C M Chavez-Eng
Journal:  Anal Chem       Date:  2003-07-01       Impact factor: 6.986

2.  Higher cefazolin concentrations with intraosseous regional prophylaxis in TKA.

Authors:  Simon W Young; Mei Zhang; Joshua T Freeman; Kelly G Vince; Brendan Coleman
Journal:  Clin Orthop Relat Res       Date:  2013-01       Impact factor: 4.176

3.  Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial.

Authors:  Lindsay Maggio; David P Nicolau; Melissa DaCosta; Dwight J Rouse; Brenna L Hughes
Journal:  Obstet Gynecol       Date:  2015-05       Impact factor: 7.661

Review 4.  Quantitative analysis of endogenous compounds.

Authors:  Rhishikesh Thakare; Yashpal S Chhonker; Nagsen Gautam; Jawaher Abdullah Alamoudi; Yazen Alnouti
Journal:  J Pharm Biomed Anal       Date:  2016-06-11       Impact factor: 3.935

5.  Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity.

Authors:  Zachary J Ward; Sara N Bleich; Angie L Cradock; Jessica L Barrett; Catherine M Giles; Chasmine Flax; Michael W Long; Steven L Gortmaker
Journal:  N Engl J Med       Date:  2019-12-19       Impact factor: 91.245

6.  A pilot study to determine the feasibility of continuous cefazolin infusion.

Authors:  Todd Waltrip; Robert Lewis; Vyvy Young; Martin Farmer; Susan Clayton; Steven Myers; Laman A Gray; Susan Galandiuk
Journal:  Surg Infect (Larchmt)       Date:  2002       Impact factor: 2.150

Review 7.  Clinical Pharmacology of Antibiotics.

Authors:  Rachel F Eyler; Kristina Shvets
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-12       Impact factor: 8.237

8.  Quantification of cefazolin in serum and adipose tissue by ultra high performance liquid chromatography-Tandem mass spectrometry (UHPLC-MS/MS): application to a pilot study of obese women undergoing cesarean delivery.

Authors:  Ryan Lillico; Casey L Sayre; Daniel S Sitar; Neal M Davies; Cynthia M Baron; Ted M Lakowski
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-07-18       Impact factor: 3.205

9.  Efficacious Cefazolin Prophylactic Dose for Morbidly Obese Women Undergoing Bariatric Surgery Based on Evidence from Subcutaneous Microdialysis and Populational Pharmacokinetic Modeling.

Authors:  Eduardo Celia Palma; Nelson Guardiola Meinhardt; Airton Tetelbom Stein; Isabela Heineck; Maria Isabel Fischer; BibianaVerlindo de Araújo; Teresa Dalla Costa
Journal:  Pharm Res       Date:  2018-04-11       Impact factor: 4.200

10.  Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.

Authors:  Alejandra Martínez-Chávez; Hilde Rosing; Michel Hillebrand; Matthijs Tibben; Alfred H Schinkel; Jos H Beijnen
Journal:  Anal Bioanal Chem       Date:  2019-06-17       Impact factor: 4.142

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.